Comparing treatments for Plasmodium vivax malaria

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of different treatment regimens for Plasmodium vivax malaria, focusing on the use of tafenoquine in combination with various antimalarial therapies. The study aims to determine whether artemisinin combination therapy (ACT) may interfere with the efficacy of tafenoquine, a single-dose medication that targets the liver stages of the malaria parasite. Participants will be monitored for four months to assess treatment outcomes and potential relapses. The trial is set in the Greater Mekong Subregion, an area significantly affected by this type of malaria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with P. vivax mono-infection as diagnosed by Rapid Diagnostic Test
* Fever or history of fever in the previous 7 days
* Quantitative G6PD activity ≥70% of the population median i.e., ≥6.1U/gHb
* Age \> 18 years, Weight \>35 kg
* Ability to understand the study instructions and provide informed consent
* Willing to be followed for 4 months and likely to adhere to the study protocol.

Exclusion Criteria:

* Coincident P. falciparum malaria or other infections
* Pregnancy
* Lactation
* Hb \< 8 g/dL
* Quantitative G6PD activity \<70% of the population median i.e., \<6.1U/gHb
* Severe malaria (as per WHO guideline)
* History of allergic or haemolytic response to any of the study drugs

Where it's running

• Shoklo Malaria Research Unit (SMRU)
  Mae Sot, Changwat Tak, Thailand Recruiting

Study contacts

• Principal investigator: Francois Nosten, Prof — Shoklo Malaria Research Unit
• Study coordinator: Aung Pyae Phyo, DPhil
• Email: aungpyaephyo@tropmedres.ac
• Phone: +66 927 127 091

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Focal mass drug administration to eliminate Vivax malaria

  This study is testing whether giving a special malaria treatment to people in certain villages can help reduce the spread of Vivax malaria in Peru.

  Recruiting Phase 3 University of California, San Francisco · Iquitos · NCT05690841

• Lotilaner safety and blood activity in healthy adults in Mali

  This Phase 1b study tests if a single dose of lotilaner is safe, tolerable, and shows mosquito-killing activity in healthy adults living in Mali.

  Recruiting Phase 1 Medicines for Malaria Venture · Bamako · NCT07758985

• See if the R21/Matrix-M malaria vaccine works in real-world settings for kids under 5

  This study tests how well the R21/Matrix-M vaccine protects children under 5 in Burkina Faso and Uganda when used in typical clinical care.

  Recruiting at 12 sites Clinton Health Access Initiative Inc. · Boromo, Boucle Mouhoun and 20 other locations · NCT07749911

• Do malaria vaccines lower the risk of invasive non-typhoidal Salmonella in young children?

  This study will see if the R21/Matrix-M malaria vaccine lowers the chance of invasive non-typhoidal Salmonella disease in children under 5 who come to health facilities with fever in the Kisantu Health Zone (DRC).

  Recruiting International Vaccine Institute · Kinshasa · NCT07416461

• Community spread of multiple infectious diseases in Cambodia from a One Health perspective

  This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.

  Recruiting Institut Pasteur du Cambodge · Phnom Penh, Phnom Penh · NCT07358910

• Lower-dose and alternate-schedule RTS,S malaria vaccine for young children

  This project will test if smaller doses and different schedules of the RTS,S malaria vaccine are safe and help build immunity in healthy children aged 5 to 60 months who live where malaria is common.

  Recruiting at 2 sites Phase 2 GlaxoSmithKline · Kigali and 1 other locations · NCT07036159

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.